EW

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Ro KhannaDemocrat $8.0k BuyMay 1, 2026 $1k-$15k -- $86.68

Insider Trades

Name	Value	Action	Price	Current Price
Lippis Daniel J.CVP, TAVR $57k619 shares SellJun 30, 2026 $91.40 $86.68
Zovighian Bernard JDirector, Officer: CEO $46k523 shares SellJun 17, 2026 $87.92 $86.68
Dahl Andrew M.SVP, Corporate Controller $49k568 shares SellMay 29, 2026 $86.08 $86.68
Bobo Donald E JrCVP,Strategy/Corp Development $2.0M23.1k shares SellMay 27, 2026 $86.42 $86.68
Chopra DaveenCVP, TMTT & Surgical $127k1.5k shares SellMay 22, 2026 $84.60 $86.68
Lippis Daniel J.CVP, TAVR $50k620 shares SellMay 18, 2026 $81.14 $86.68

News

gurufocus.comEW DCF Analysis: Intrinsic Value $51 vs Price $89gurufocus.comJun 17

benzinga.comEdwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Devicebenzinga.comJun 16

zacks.comShould You Continue to Hold EW Stock in Your Portfolio?zacks.comJun 12

newsfilecorp.comEast West Announces $858,000 Non-Brokered Private Placementnewsfilecorp.comJun 12

gurufocus.comEdwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100gurufocus.comMay 22

Trade EW

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

CEO: Bernard J. Zovighian
IPO Date: Mar 27, 2000

Market Data

Open: $86.96
High: $87.83
Low: $86.57
Volume: 2.6M
Avg Volume: 5.1M
52W High: $89.60
52W Low: $72.30

Valuation

Market Cap: $50B
Enterprise Value: $49B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $1.3B
Revenue: $6.1B
Net Income: $1.1B
Cash: $2.9B
Debt: $705M

Events

EarningsJul 23

EPS est. 0.73